ES2099211T3 - Conjugados citomoduladores de miembros de parejas de union especifica. - Google Patents

Conjugados citomoduladores de miembros de parejas de union especifica.

Info

Publication number
ES2099211T3
ES2099211T3 ES92303618T ES92303618T ES2099211T3 ES 2099211 T3 ES2099211 T3 ES 2099211T3 ES 92303618 T ES92303618 T ES 92303618T ES 92303618 T ES92303618 T ES 92303618T ES 2099211 T3 ES2099211 T3 ES 2099211T3
Authority
ES
Spain
Prior art keywords
conjugates
cytomodulating
couples
members
specific union
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92303618T
Other languages
English (en)
Other versions
ES2099211T5 (es
Inventor
Philippe Pouletty
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sangstat Medical Corp
Original Assignee
Sangstat Medical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24772845&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2099211(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sangstat Medical Corp filed Critical Sangstat Medical Corp
Publication of ES2099211T3 publication Critical patent/ES2099211T3/es
Application granted granted Critical
Publication of ES2099211T5 publication Critical patent/ES2099211T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Abstract

SE PRESENTAN NUEVOS CONJUGADOS QUE CONTIENE UNA UNIDAD CAPAZ DE ENLAZARSE ESPECIFICAMENTE A UNA CELULA OBJETIVO UNIDA A UNA UNIDAD SELECTIVA PARA ENLAZARSE A UN AGENTE PROVOCADOR DE EFECTOS ENDOGENO, CAPAZ DE CAUSAR LA INACTIVACION DE LA CELULA O CITOTOXICIDAD. EJEMPLOS DE CONJUGADOS SON UN LIGANDO PARA UNA PROTEINA DE MEMBRANA SUPERFICIAL, EJ. UN RECEPTOR DE IL-2, UNIDO A UN ANTIGENO A O B POLISACARIDO. LOS CONJUGADOS SE PUEDEN UTILIZAR ESPECIFICAMENTE PARA DESTRUIR LAS CELULAS ASOCIADAS A UNA CONDICION PATOGENICA.
ES92303618T 1991-04-23 1992-04-22 Conjugados citomoduladores de miembros de parejas de union especifica. Expired - Lifetime ES2099211T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69053091A 1991-04-23 1991-04-23
US690530 1991-04-23

Publications (2)

Publication Number Publication Date
ES2099211T3 true ES2099211T3 (es) 1997-05-16
ES2099211T5 ES2099211T5 (es) 2004-02-01

Family

ID=24772845

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92303618T Expired - Lifetime ES2099211T5 (es) 1991-04-23 1992-04-22 Conjugados citomoduladores de miembros de parejas de union especifica.

Country Status (7)

Country Link
EP (1) EP0510949B2 (es)
JP (1) JP3105629B2 (es)
AT (1) ATE147993T1 (es)
CA (1) CA2066810A1 (es)
DE (1) DE69216899T3 (es)
DK (1) DK0510949T3 (es)
ES (1) ES2099211T5 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858363A (en) * 1990-07-20 1999-01-12 Pharmacia & Upjohn Ab Target specific antibody-superantigen conjugates and their preparation
US5612034A (en) * 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
EP0602290B1 (en) * 1992-12-04 1999-08-25 ConjuChem, Inc. Antibody-conjugated Hepatitis B surface antigen and use thereof
ATE255910T1 (de) * 1996-04-10 2003-12-15 Sangstat Medical Corp Zellmodulierende konjugate aus elementen aus spezifischen bindungspaaren
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6096725A (en) * 1997-07-02 2000-08-01 Neose Technologies, Inc. Methods of using αGal oligosaccharides as immune system targeting agents
GB9724838D0 (en) * 1997-11-26 1998-01-21 Franks Christopher R Compositions
MY136203A (en) 1998-08-11 2008-08-29 Idec Pharma Corp Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
EP1616572B1 (en) 1998-11-09 2010-09-01 Biogen Idec Inc. Chimeric anti-CD20 antibody, rituxan, for use in the treatment of chronic lymphocytic leukemia
JP2002539076A (ja) 1999-01-06 2002-11-19 ユニバーシティ・オブ・サザン・カリフォルニア 新脈管形成抑制のための方法および組成物
US8383081B2 (en) 1999-05-10 2013-02-26 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods of use
US8119101B2 (en) 1999-05-10 2012-02-21 The Ohio State University Anti-CD74 immunoconjugates and methods of use
US7829064B2 (en) 1999-05-10 2010-11-09 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods
EP1203025B1 (en) 1999-07-13 2009-07-01 University Of Southern California Novel method and composition for inhibition of angiogenesis using antagonists based on mmp-9 and beta1 integrins
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
BR0109704A (pt) 2000-03-31 2003-04-29 Purdue Research Foundation Método de tratamento usando conjugados de imunógeno ligando
CN100560131C (zh) 2001-10-22 2009-11-18 斯克里普斯研究学院 抗体靶向化合物
US7390885B2 (en) 2001-11-26 2008-06-24 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US7365167B2 (en) 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US7488792B2 (en) 2002-08-28 2009-02-10 Burnham Institute For Medical Research Collagen-binding molecules that selectively home to tumor vasculature and methods of using same
MXPA05005160A (es) 2002-11-15 2005-07-22 Genmab As Anticuerpos monoclonales humanos contra la cd25.
US8420086B2 (en) 2002-12-13 2013-04-16 Immunomedics, Inc. Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
JP2007516157A (ja) 2003-02-06 2007-06-21 トリペップ アクチ ボラゲット グリコシル化された抗原／抗体又はリガンド／受容体特異性交換体
US9550838B2 (en) 2004-02-13 2017-01-24 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US8883160B2 (en) 2004-02-13 2014-11-11 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US8475794B2 (en) 2005-04-06 2013-07-02 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
US8349332B2 (en) 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
WO2009052374A2 (en) * 2007-10-18 2009-04-23 Mayo Foundation For Medical Education And Research Igm-mediated receptor clustering and cell modulation
CA2853138A1 (en) 2011-12-05 2013-06-13 Immunomedics, Inc. Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
US9757458B2 (en) 2011-12-05 2017-09-12 Immunomedics, Inc. Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
US10206918B2 (en) 2012-12-13 2019-02-19 Immunomedics, Inc. Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
US9107960B2 (en) 2012-12-13 2015-08-18 Immunimedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US9492566B2 (en) 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US10413539B2 (en) 2012-12-13 2019-09-17 Immunomedics, Inc. Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
US10137196B2 (en) 2012-12-13 2018-11-27 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US9931417B2 (en) 2012-12-13 2018-04-03 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
EP4035689A1 (en) 2012-12-13 2022-08-03 Immunomedics Inc. Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
US10744129B2 (en) 2012-12-13 2020-08-18 Immunomedics, Inc. Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
US11253606B2 (en) 2013-07-23 2022-02-22 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
CN107428837A (zh) 2015-04-22 2017-12-01 免疫医疗公司 循环trop‑2阳性癌细胞的分离、检测、诊断和/或鉴定
US10195175B2 (en) 2015-06-25 2019-02-05 Immunomedics, Inc. Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
US20170224837A1 (en) 2016-02-10 2017-08-10 Immunomedics, Inc. Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers
WO2017189279A1 (en) 2016-04-27 2017-11-02 Immunomedics, Inc. Efficacy of anti-trop-2-sn-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors
RU2758234C2 (ru) 2017-03-27 2021-10-26 Иммьюномедикс, Инк. ЛЕЧЕНИЕ ТРИЖДЫ НЕГАТИВНОГО РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ, ХАРАКТЕРИЗУЮЩЕГОСЯ ЭКСПРЕССИЕЙ Trop-2, С ПОМОЩЬЮ САЦИТУЗУМАБА ГОВИТЕКАНА И ИНГИБИТОРА Rad51
EP3606964A4 (en) 2017-04-03 2020-12-09 Immunomedics, Inc. SUBCUTANE ADMINISTRATION OF ANTIBODY DRUG CONJUGATES FOR CANCER THERAPY

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE74622T1 (de) † 1984-10-31 1992-04-15 Massachusetts Inst Technology Verfahren zum sensibilisieren einer zielzelle zum lysen durch cytotoxische t-lymphkoerperchen.
GB8626413D0 (en) † 1986-11-05 1986-12-03 Gilliland L K Antibodies
DE3880766D1 (de) * 1987-09-02 1993-06-09 Ciba Geigy Ag Konjugate von interferon alpha mit immunglobulinen.
DK8189A (da) * 1988-01-12 1989-07-13 Bunge Australia Antigen-antistof-konjugater, deres fremstilling og anvendelse
EP0334300A1 (en) † 1988-03-21 1989-09-27 Neorx Corporation The use of monoclonal antibodies and conjugates thereof as signals to direct sensitized effector cells to tumor sites
DE3825615A1 (de) † 1988-07-28 1990-02-01 Behringwerke Ag Antigenkonstrukte von "major histocompatibility complex" klasse i antigenen mit spezifischen traegermolekuelen, ihre herstellung und verwendung
KR900005995A (ko) * 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
GB8907310D0 (en) † 1989-03-31 1989-05-17 Medical Res Council Heteroconjugates
IE63847B1 (en) * 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
EP0482068A1 (en) * 1989-07-14 1992-04-29 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
CA2090105A1 (en) * 1990-08-29 1992-03-01 Jean-Paul Soulillou Protein polyligands joined to a stable protein core

Also Published As

Publication number Publication date
DE69216899T3 (de) 2004-01-15
EP0510949A3 (en) 1992-12-09
JP3105629B2 (ja) 2000-11-06
CA2066810A1 (en) 1992-10-24
EP0510949B2 (en) 2003-04-02
DE69216899D1 (de) 1997-03-06
JPH07173071A (ja) 1995-07-11
DK0510949T3 (da) 1997-07-28
ES2099211T5 (es) 2004-02-01
EP0510949A2 (en) 1992-10-28
DE69216899T2 (de) 1997-06-12
ATE147993T1 (de) 1997-02-15
EP0510949B1 (en) 1997-01-22

Similar Documents

Publication Publication Date Title
ES2099211T3 (es) Conjugados citomoduladores de miembros de parejas de union especifica.
EP0833666A3 (en) CYTOMODULATING CONJUGATES OF SPECIFIC LINK PAIR ELEMENTS
BR8707431A (pt) Conjugados asteroides
DE3683785D1 (de) Rueckseitenmaterial fuer einen ultraschallwandler.
DE68912232D1 (de) Konjugate zytotoxischer Arzneimittel.
DE3782394D1 (de) Immobilisiertes, physiologisch aktives material.
ATE124611T1 (de) Verbesserungen an mattenklemmen.
ATE79135T1 (de) Bifunktionelle proteine.
DE3586259T2 (de) Propylencopolymerzusammensetzung fuer schweissbare kunststofflaminate.
DE3889045D1 (de) Thermoplastische Äthylenpolymer-Zusammensetzung.
NO881077D0 (no) Kjemo-radio-immuno-konjugater.
YU12397A (en) NOVEL PYRIMIDO [1,2-a] INDOLES
FI894211A0 (fi) Mikrobiologiskt foerfarande foer framstaellning av agrokemiskt anvaendbara aktivaemnen.
DE69020209D1 (de) Breitbandverstärker mit FET.
DE58903624D1 (de) Strahlenhaertende, thermoaktivierbare klebstoffmischungen.
FI880795A (fi) Banformat material, speciellt foer undertak.
ATE81325T1 (de) Verpackung fuer kleinteile.
ATE65012T1 (de) Aus partikeln bestehendes steriles material.
ATE77633T1 (de) Propylencopolymerzusammensetzung fuer schweissbare kunststofflaminate.
NO880417D0 (no) Vogn for pelsdyrfarmer.
IT8785610A0 (it) Autoimbustante postale con due linguette di chiusura.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 510949

Country of ref document: ES